Comparative Pharmacology
Head-to-head clinical analysis: FLURBIPROFEN SODIUM versus LODINE XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLURBIPROFEN SODIUM versus LODINE XL.
FLURBIPROFEN SODIUM vs LODINE XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, thereby decreasing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis leading to anti-inflammatory, analgesic, and antipyretic effects.
50 mg orally every 4 to 6 hours as needed; maximum 300 mg per day.
400 mg or 600 mg orally once daily.
None Documented
None Documented
3-4 hours; in elderly or hepatic impairment may extend to 5-6 hours.
Terminal elimination half-life is approximately 6-7 hours. Steady-state is achieved within 2 days.
Renal: 70% as conjugates (glucuronide) and unchanged drug (<1%); biliary/fecal: minimal.
Renal excretion of metabolites accounts for approximately 70% of a dose; fecal excretion accounts for about 20%.
Category D/X
Category C
NSAID
NSAID